Strong Revenue Growth
Merit Medical reported total revenue of $339.8 million for Q3 2024, up 7.8% year-over-year on a GAAP basis and 7.9% on a constant currency basis.
Profitability Exceeds Expectations
Non-GAAP operating profit grew by 19%, with a non-GAAP operating margin of 19.2%, up approximately 175 basis points year-over-year.
Significant Free Cash Flow
Generated $38 million of free cash flow in Q3 2024 and over $120 million in the first 9 months, a 116% increase year-over-year.
Positive WRAPSODY Trial Results
WRAPSODY WAVE trial showed a 89.8% target lesion primary patency rate, 27 percentage points higher than the control group.
Strategic Acquisition of Cook Medical's Lead Management Portfolio
Acquired for $210 million, expected to add approximately $40 million to annual revenue starting in FY 2025.